# Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

> **NCT07039669** · PHASE3 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 594 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive (COPD)

## Interventions

- **DRUG:** 611
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07039669
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2028-09
- **Final completion:** 2028-11
- **Target enrollment:** 594 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07039669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07039669, "Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07039669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*